Nurix Therapeutics shares are up in premarket trading after announcing a collaboration with Roche to co-develop and co-commercialize bexobrutideg, an investigational BTK degrader. The deal supports Nurix's pipeline and adds external validation for its drug-discovery platform. The move is positive for the stock, though the article provides no deal economics or regulatory milestone.
Nurix Therapeutics shares are up in premarket trading after announcing a collaboration with Roche to co-develop and co-commercialize bexobrutideg, an investigational BTK degrader. The deal supports Nurix's pipeline and adds external validation for its drug-discovery platform. The move is positive for the stock, though the article provides no deal economics or regulatory milestone.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialOverall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
